<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="86">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671889</url>
  </required_header>
  <id_info>
    <org_study_id>AL002</org_study_id>
    <nct_id>NCT03671889</nct_id>
  </id_info>
  <brief_title>ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease</brief_title>
  <official_title>Assessment of Safety and Efficacy of ExAblate Blood-Brain Barrier Disruption for the Treatment of Patients With Probable Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000&#xD;
      Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable&#xD;
      Alzheimer's Disease (AD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single-arm study to evaluate the safety and efficacy of&#xD;
      BBB disruption using the ExAblate Model 4000 Type 2.0 (220 kHz) system. Patients with&#xD;
      diagnosis of Probable Alzheimer's Disease may qualify for a clinical trial to have three&#xD;
      serial ExAblate BBB disruption procedures in specific areas in the brain. This study will be&#xD;
      conducted at up to 8 sites in the United States and will enroll up to 30 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects who meet study eligibility will undergo treatment procedures in groups by staged volumes.</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device and procedure related adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of adverse events following each treatment through end of study</description>
  </primary_outcome>
  <other_outcome>
    <measure>BBB Disruption and Closure</measure>
    <time_frame>Immediately after the end of each ExAblate treatment and 24 hours post treatment</time_frame>
    <description>MR images post-procedure to verify that the BBB was disrupted and subsequently closed within 24 hours.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Blood Brain Barrier (BBB) Disruption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ExAblate Model 4000 Type 2.0 System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood Brain Barrier (BBB) Disruption</intervention_name>
    <description>Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.</description>
    <arm_group_label>Blood Brain Barrier (BBB) Disruption</arm_group_label>
    <other_name>ExAblate Neuro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female between 50-85 years of age&#xD;
&#xD;
          2. Probable Alzheimer's Disease (AD)&#xD;
&#xD;
          3. If taking concurrent Alzheimer's medication, has been on the medication for at least 2&#xD;
             months with a stable dose for at least 3 months&#xD;
&#xD;
          4. Able to communicate sensations during the ExAblate MRgFUS procedure&#xD;
&#xD;
          5. Ambulatory&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. MRI Findings&#xD;
&#xD;
          2. Presence of unknown or MR unsafe devices anywhere in the body&#xD;
&#xD;
          3. Significant cardiac disease or unstable hemodynamic status&#xD;
&#xD;
          4. Relative contraindications to ultrasound contrast agent or PET amyloid tracer&#xD;
&#xD;
          5. History of a bleeding disorder&#xD;
&#xD;
          6. History of liver disease&#xD;
&#xD;
          7. Known cerebral or systemic vasculopathy&#xD;
&#xD;
          8. Significant depression and at potential risk of suicide&#xD;
&#xD;
          9. Any contraindications to MRI scanning&#xD;
&#xD;
         10. Any contraindication to lumbar puncture for collection of cerebral spinal fluid&#xD;
&#xD;
         11. Untreated, uncontrolled sleep apnea&#xD;
&#xD;
         12. History of seizure disorder or epilepsy&#xD;
&#xD;
         13. Severely Impaired renal function&#xD;
&#xD;
         14. Currently in a clinical trial involving an investigational product or non-approved use&#xD;
             of a drug or device or in any other type of medical research&#xD;
&#xD;
         15. Chronic pulmonary disorders&#xD;
&#xD;
         16. Positive human immunodeficiency virus (HIV)&#xD;
&#xD;
         17. Known apolipoprotein E allele (ApoE4) homozygosity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Delray Medical Center &amp; Florida Atlantic University</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Zucker, MS</last_name>
      <phone>561-235-3767</phone>
      <email>JennyZucker712@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lloyd Zucker, MD, FAANS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Broward Health Medical Center &amp; The University of Florida</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celena Bodie</last_name>
      <phone>954-786-6736</phone>
      <email>cbodie@browardhealth.org</email>
    </contact>
    <investigator>
      <last_name>Shaye Moskowitz, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health South Florida &amp; Florida International University</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Mederos</last_name>
      <phone>786-596-1845</phone>
      <email>Margarita.mederos@BaptistHealth.net</email>
    </contact>
    <investigator>
      <last_name>Michael W. McDermott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachael Olovyannikov</last_name>
      <phone>212-746-7373</phone>
      <email>rao4005@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Kaplitt, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University -Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Most, MS</last_name>
      <phone>636-634-0478</phone>
      <email>elaine.most@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Bhavya R Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Rockefeller Neuroscience Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiley Everson, RN, BSN</last_name>
      <phone>304-293-9146</phone>
      <email>kiley.everson@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Ali R Rezai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>July 11, 2022</last_update_submitted>
  <last_update_submitted_qc>July 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Alzheimer Syndrome</keyword>
  <keyword>Magnetic Resonance guided Focal Ultrasound (MRgFUS)</keyword>
  <keyword>Blood-Brain Barrier</keyword>
  <keyword>ExAblate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

